Functional Mitral Stenosis From Annular Calcification: Medical Management or Transcatheter Replacement?
Balloon valvuloplasty won't work on a calcified annulus, and conventional surgery carries real risk in this anatomy — leaving medical therapy and an emerging transcatheter option as the actual choice.
M.W., an 83-year-old woman, still hems her grandchildren's school clothes by hand, sitting by the window in the afternoon when her energy is at its best — a routine her daughter says has visibly shrunk over the past several months, from an hour at a stretch to fifteen minutes before she needs to rest. Her mitral annular calcification was first noted incidentally on an echocardiogram eight years ago, asymptomatic then, watched periodically since. What's changed is that her most recent echo shows the calcification has progressed enough to functionally narrow her mitral valve, and her symptoms — dyspnea on mild exertion, fatigue, days her daughter describes as 'foggier' than they used to be — track with that progression rather than with any new unrelated finding.
Functional mitral stenosis from annular calcification behaves differently from the rheumatic disease the same physiology usually implies. The valve leaflets themselves are often relatively normal; it's the rigid, calcified annulus restricting their motion, which means balloon valvuloplasty, effective in rheumatic MS, generally does not work here — there is no commissural fusion, the fusing-together of the leaflet edges at their hinge points that rheumatic scarring produces, for a balloon to split open; only a stiff ring that a balloon cannot soften. Conventional surgical replacement is technically difficult and carries meaningfully higher risk in heavily calcified annuli, where suturing a new valve into a rigid, sometimes friable ring raises the risk of atrioventricular groove disruption, a rare but catastrophic complication. Transcatheter mitral valve replacement into the native, calcified annulus is a newer option with real but still-evolving outcome data, particularly in a woman her age with the frailty her team is now trying to characterize more carefully than her chart currently reflects.
In clinic, reviewing the progression
Balloon valvuloplasty isn't going to help her — there's no fused commissure here to split, just a calcified ring restricting leaflet motion, and that's a mechanical problem a balloon doesn't fix. Conventional surgical replacement in a heavily calcified annulus carries real risk of atrioventricular groove disruption, which in a woman her age I take seriously before recommending it. I think transcatheter valve-in-MAC replacement deserves genuine consideration here, not as a last resort but as a real option given the anatomy.
If her annular calcification were mild and her symptoms were driven mostly by something else, I wouldn't be raising any intervention at all — this conversation exists because her functional stenosis has clearly progressed and correlates with a real decline in what she can do.
Before we frame this as a valve-intervention decision, I want her frailty properly characterized, because it changes both the risk calculus for any procedure and how much benefit she's likely to actually experience from one. 'Foggier days' and reduced activity tolerance in an 83-year-old could reflect her valve, but they could also reflect early cognitive change, deconditioning, or both — and going into a transcatheter procedure without a clear picture of her baseline function and goals risks treating a valve number without treating the whole patient it belongs to.
I'm not arguing against considering the procedure — I'm arguing for sequencing. A frailty assessment doesn't meaningfully delay her care, and it gives everyone, including her and her daughter, a much better basis for weighing procedural risk against expected benefit than proceeding straight from echo findings to an intervention conversation.
Regardless of which way the intervention conversation goes, rate control belongs in her regimen now, not after that decision is made. Functional mitral stenosis from MAC behaves like rheumatic MS in one important respect: tachycardia shortens diastolic filling time across the narrowed orifice the same way, and a beta-blocker addresses that mechanism directly while everyone else gathers the information they need. It isn't free, though, and I want that said out loud in her case specifically: fatigue and blunted cognition are recognized beta-blocker effects, and those are exactly the two symptoms the frailty and cognitive workup is trying to attribute. Start low, and treat any worsening of her fogginess as a possible drug effect rather than disease progression. I'd start a low-dose beta-blocker now, add cautious diuresis if her congestive symptoms warrant it, and let the frailty assessment and procedural discussion proceed in parallel rather than waiting on each other.
Agreed: low-dose metoprolol started today regardless of what follows, frailty and cognitive assessment arranged, and the transcatheter valve-in-MAC conversation held pending those results and a direct discussion with her and her daughter about goals.
Transcatheter valve-in-MAC replacement moves forward as a real option, with her and her daughter's stated goals weighed explicitly against the procedural risk.
Medical management — rate control and diuresis — becomes the ongoing plan, focused on comfort and function rather than mechanical correction.
Either way, the plan will rest on a clearer picture of her actual baseline than today's echo report alone provides.